san model updat reflect sale eu
messag updat model ahead result guidanc
provid better reflect sale san eu gener busi balanc
dont see signific risk busi maintain neutral rate
stock base expect increas competit threat key growth
driver dupix asthma/atop dermat broader hemophilia franchis
remov pt estim fair valu rang sanofi
result confer call et
expect guidanc broadli line consensu forecast currenc like
tailwind base analysi us volum demand expect rel
in-lin quarter trend dupix volum suggest us us number could beat
estim san neutral estim sale ep
respect sales/ep estim lower
mainli driven remov san eu gener busi begin
consist mgmt guidanc divest busi sales/ep
estim compar consensu estim
respect current rate currenc analysi suggest fx headwind
revers lift sale growth
isatuximab hit r/r mm patient magnitud benefit tbd darzelex
set high bar morn san announc pivot phase trial
isatuximab antibodi combin pomalidomid pomalyst celg
neutral low-dos dexamethason met primari endpoint prolong
progress free surviv patient relapsed/refractori multipl myeloma r/r mm
compani note result submit upcom medic meet
anticip form basi regulatori submiss plan later year
random multi-cent open label phase studi known icaria-mm one four
on-going phase trial evalu isatuximab combin soc patient r/
 newli diagnos mm jnj cs darzalex anti-cd antibodi
becom part standard care r/r mm show month progress free
surviv benefit phase ib equuleu studi form basi approv
set jnj expans effort mm result one broadest
label mm agent set high bar isatuximab
page analyst certif import disclosur
valuat risk
remov pt estim fair valu rang sanofi base dcf valuat
sale profit assum wacc line larg cap pharma peer
termin growth rate
upsid risk valuat includ reacceler dupix launch asthma
better expect launch cablivi rare blood disord attp libtayo cutan
downsid risk includ lower expect dupix growth greater expect
insulin price pressur impact toujeo greater expect eloct slowdown
hemlibra
page analyst certif import disclosur
figur except ep
share profit loss associ joint ventur
compani report guggenheim llc estim
page analyst certif import disclosur
